Clinical Trial Update: NRX101 Glx Biomarker Validation Study [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial update for NRX101 focusing on Glx biomarker validation in bipolar depression and suicidal ideation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression
• Suicidal Ideation

Drugs mentioned

• NRX101

Snippet

Sponsor: NeuroRx, Inc. | Conditions: Bipolar Depression, Suicidal Ideation | Phase 2, Phase 3 | Status: COMPLETED